Evidence map›Paper›PMID 40294213›Full record

ArticleEuropean journal of preventive cardiology2026

Risk calculator of multimorbid risk of rehospitalization and death from heart failure: including the contribution of the gut microbiome.

Muhammad Zubair Israr, Andrea Salzano, Hong Zhan, Adriaan A Voors, Leong L Ng, Toru Suzuki

Abstract readValidation Study
In one paragraph

Article in European journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Muhammad Zubair IsrarDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, LE3 9QP Leicester, UK.ORCID 0000-0003-1111-2780
Andrea SalzanoDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, LE3 9QP Leicester, UK.ORCID 0000-0003-2352-2103
Hong ZhanTellgen and Masswill Corporations, Shanghai, China.
Adriaan A VoorsDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Leong L NgDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, LE3 9QP Leicester, UK.
Toru SuzukiDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, LE3 9QP Leicester, UK.ORCID 0000-0002-8371-664X

Funding

BHFBIOSTAT-CHFBritish Heart FoundationEuropean Commission 2010-020808-29Japan Heart FoundationLeDucq FoundationLeicester Biomedical Research CentreMedical Research CouncilMetAbolic PhenotypingMRCNational Institute for Health ResearchUK Consortium
6 · The paper itself

Abstract

aimsThe elucidation of the contributory role of multimorbidity to heart failure (HF) including the gut-heart axis has added a new dimension to our understanding of HF pathophysiology that is not reflected in currently available risk scores. The present investigation aimed to develop and validate a novel risk score model of multimorbidity for HF risk stratification. METHODS AND

resultsA risk model was developed based on the contribution of markers associated with HF multimorbidities on outcomes of mortality and/or rehospitalization due to HF (death/HF) at one year. Two independent HF cohorts were combined and randomly split 70:30 using a split-sample validation approach for training and validation cohorts that were not significantly different for investigated variables. Backward logistic regression was used to develop the risk model with a further scoring system to create a simple risk calculator. A final 11-variable risk model (age, previous HF hospitalization, NYHA group III/IV, NT-proBNP, diastolic blood pressure, loop diuretic use, beta-blocker non-use, creatinine, COPD, diabetes, and combined gut metabolites) showed a diagnostic performance of 0.71 in the training cohort (C-statistic validation cohort, 0.70, P < 0.001). A risk score/calculator was further developed based on this model with categorization into three (low-, mid-, and high-) and two (low- and high-) risk groups, with both approaches demonstrating increased incidence of death/HF in patients at the highest risk (P < 0.001).

conclusionA novel risk model and score were derived that showed the contribution of comorbidities including the added value of the gut-heart axis on risk stratification of HF patients on rehospitalization and death. LAY SUMMARY: The contributory role of multimorbidity is not well understood in heart failure (HF), including the more recent addition of the gut microbiome (gut-heart axis). However, in current HF risk scores, the contributory role of multimorbidity is seldom considered. In this study, we developed an 11-variable risk model and a simple risk score calculator for clinical use that considers the contribution of HF multimorbidity, including the gut microbiome. The clinical risk score was developed and validated in a clinical cohort from two combined independent European studies from inpatient heart failure subjects. The outcomes were death due to HF and/or rehospitalization at 1 year. The final model showed diagnostic performance comparable to current HF risk scores. Furthermore, the risk score calculator, developed for clinical use, is able to stratify patients into low-, mid-, and high-risk groups, with worsening outcomes seen with increasing risk group. The importance and novelty of this risk model over current HF risk scores are the contribution of comorbidities including the added value of the gut-heart axis on HF risk stratification.

Indexed as

Gastrointestinal MicrobiomeHeart FailurePatient ReadmissionAgedAged, 80 and overFemaleHumansMaleMiddle AgedMultimorbidityPredictive Value of TestsPrognosisReproducibility of ResultsRisk AssessmentRisk FactorsTime FactorsGutHeart failureMetabolitesOutcomesRisk model

Identifiers

PMID40294213
PMCPMC12863934

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.